支气管动脉化疗栓塞与全身静脉化疗治疗中晚期非小细胞肺癌的临床效果比较  

Comparison of Clinical Efficacy between Bronchial Artery Chemoembolization and Systemic Intravenous Chemotherapy in the Treatment of Mid to Late Stage Non-Small Cell Lung Cancer

作　　者：张志辉 ZHANG Zhi-hui(Department of Oncology,Lingcheng District Traditional Chinese Medicine Hospital,Dezhou Shandong 253500,China)

机构地区：[1]德州市陵城区中医院肿瘤科,山东德州253500

出　　处：《中华养生保健》2025年第5期51-55,共5页CHINESE HEALTH CARE

摘　　要：目的比较中晚期非小细胞肺癌(NSCLC)患者给予支气管动脉化疗栓塞(BACE)与全身静脉化疗治疗的临床效果。方法选取2017年10月—2023年1月德州市陵城区中医院收治的中晚期NSCLC患者共计64例,以随机数表法分成观察组(32例)与对照组(32例)。观察组给予BACE治疗,对照组给予全身静脉化疗治疗,比较两组临床疗效、血清肿瘤标志物、炎症因子、生活质量、安全性、成本-效益,统计1年生存率。结果观察组客观缓解率(ORR)、疾病控制率(DCR)较对照组更高(P<0.05);治疗后两组糖类抗原125(CA125)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)水平下降(P<0.05),观察组较对照组更低(P<0.05);治疗后两组肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白细胞介素-8(IL-8)水平下降(P<0.05),观察组较对照组更低(P<0.05);治疗后两组Karnofsky功能状态评分标准(KPS)评分升高(P<0.05),观察组较对照组更高(P<0.05);观察组不良反应(骨髓抑制、消化道反应、贫血)发生率较对照组更低(P<0.05),观察组未出现肺栓塞等严重并发症,1例出现出血,经内科治疗后出血停止;统计1年生存率,观察组较对照组更高(P<0.05);观察组成本效益比优于对照组。结论对于中晚期NSCLC患者,与全身静脉化疗相比,BACE治疗能够提升临床疗效,调节血清肿瘤标志物、炎症因子水平,提高生活质量,提高患者1年生存率,安全性较高,成本-效益更佳。Objective To compare the clinical efficacy of bronchial artery chemoembolization(BACE)and systemic intravenous chemotherapy in patients with mid to late stage non-small cell lung cancer(NSCLC).Methods A total of 64 patients with mid to late stage NSCLC from October 2017 to January 2023 who were admitted in Lingcheng District Traditional Chinese Medicine Hospital in Dezhou city were selected.By random number table method,they were divided into the observation group(32 cases,BACE)and the control group(32 cases,systemic intravenous chemotherapy).The clinical efficacy,serum tumor markers,inflammatory factors,quality of life,safety,cost-effectiveness,and one-year survival rate in both groups were compared.Results In the objective response rate(ORR)and disease control rate(DCR),in comparison of the control group,the observation group were higher(P<0.05).After treatment,the carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and carbohydrate antigen 19-9(CA19-9)levels in both groups were decreased(P<0.05),and in comparison of the control group,the observation group was lower(P<0.05).After treatment,the tumor necrosis factors-α(TNF-α),C-reactive protein(CRP)and interleukin-8(IL-8)levels were decreased in both groups(P<0.05),and in comparison of the control group,the observation group was lower(P<0.05).After treatment,the Karnofsky functional status score(KPS)in both groups were increased(P<0.05),and in comparison of the control group,the observation group was higher(P<0.05).In the incidence of adverse reactions(bone marrow suppression,gastrointestinal reactions,anemia),in comparison of the control group,the observation group was lower(P<0.05).There were no serious complications such as pulmonary embolism in the observation group,and one case experienced bleeding.After internal medicine treatment,the bleeding stopped.In the one-year survival rate,in comparison of the control group 62.50%(20/32),the observation group 88.00%(22/25)was higher(P<0.05).The cost-effectiveness ratio of the observation group was bette

关 键 词：中晚期非小细胞肺癌 支气管动脉化疗栓塞 全身静脉化疗 血清肿瘤标志物 炎症因子 

分 类 号：R734.2[医药卫生—肿瘤]